| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | E2F3 |
| Uniprot No | O00716 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-133aa |
| 氨基酸序列 | MQSGGGVKTDDTSTLNSLCGYAWVYVWEEKQRCRLSSFFSSSASIPGLLP SHTLDLVQNVGVVLDEALGWGRERELCVKCLLEMHCGVFSCMGNHLCQAF PHFPYLSHLVSCLCFQLCVILFASCTKLIFSKV |
| 预测分子量 | 41 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于E2F3重组蛋白的3篇参考文献示例(内容基于公开研究整理，非真实文献)：
---
1. **文献名称**：*E2F3 regulates cell cycle progression via transcriptional activation of cyclin E and Cdc25A*
**作者**：Hiebert, S.W., et al.
**摘要**：该研究通过重组E2F3蛋白体外实验，证明E2F3直接结合并激活细胞周期关键基因(如Cyclin E和Cdc25A)的启动子，促进G1/S期转换。重组E2F3与Rb蛋白的相互作用被证实是其功能调控的核心机制。
2. **文献名称**：*Amplification and oncogenic role of E2F3 in human bladder cancer*
**作者**：Wu, L., et al.
**摘要**：研究利用重组E2F3蛋白进行功能验证，发现其在膀胱癌中频繁扩增。过表达的E2F3通过促进细胞增殖和抑制凋亡驱动肿瘤发展，靶向E2F3重组蛋白的体外实验显示其对癌细胞生长的显著影响。
3. **文献名称**：*Recombinant E2F3 isoforms exhibit distinct DNA binding and transactivation properties*
**作者**：Cooper, C.D., et al.
**摘要**：通过纯化重组E2F3a和E2F3b亚型蛋白，研究发现二者在DNA结合活性和靶基因调控中存在差异。E2F3a主要促进细胞周期进程，而E2F3b可能参与转录抑制，揭示了亚型特异性功能的分子基础。
---
**备注**：以上文献为示例，实际文献需通过PubMed或Google Scholar检索确认。建议使用关键词“E2F3 recombinant protein”、“E2F3 function”或“E2F3 cancer”查找最新研究。
E2F3 is a member of the E2F transcription factor family, which plays a central role in regulating cell cycle progression, DNA replication, and apoptosis. As part of the E2F family, it functions in coordination with retinoblastoma (Rb) proteins; when Rb is inactivated via phosphorylation during the G1-S phase transition, E2F3 is released to activate the transcription of genes required for S-phase entry. E2F3 exists in two isoforms, E2F3a and E2F3b, produced by alternative promoters. E2F3a is considered a potent transcriptional activator driving proliferation, while E2F3b may act as a repressor or have context-dependent roles in differentiation and stress responses.
Recombinant E2F3 proteins are engineered versions of these isoforms, typically expressed in heterologous systems like *E. coli* or mammalian cell cultures for functional studies. These proteins retain the DNA-binding and transactivation domains essential for their biological activity, enabling researchers to investigate their interactions with DNA, Rb-family proteins, or other cofactors in vitro. Recombinant E2F3 is widely used to dissect its role in cancer, as overexpression or amplification of E2F3 is linked to tumorigenesis in multiple cancers, including bladder, ovarian, and prostate cancers. Its dysregulation disrupts cell cycle control, promoting uncontrolled proliferation and genomic instability.
Studies using recombinant E2F3 have also explored its therapeutic potential. For instance, inhibiting E2F3 activity in cancer models suppresses tumor growth, highlighting its value as a drug target. Additionally, structural analyses of recombinant E2F3 have provided insights into its binding mechanisms with DNA and partner proteins like DP1. aiding in the design of small-molecule inhibitors. Beyond oncology, recombinant E2F3 contributes to understanding developmental processes, stem cell differentiation, and tissue regeneration. Its dual roles in activation and repression, depending on isoform and cellular context, underscore the complexity of E2F3 biology and the necessity for precisely engineered tools to unravel its functions.
×
